A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis

This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United States Food and Drug Administration. Participants will be assigned at random to receive either the study drug or placebo. A placebo is a harmless inactive substance. The study drug/placebo is given over 60 minutes intravenously (in your vein). Participation will last about 6 months and requires about 12 visits to Penn.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  sarcoidosis
• Age: Between 18 Years - 93 Years
• Gender: All